Kleihues P, Burger PC, Aldape KD, et al: Glioblastoma, in Louis DN, Ohgaki H, Wiester OD, et al (eds): WHO Classification of Tumours of the Central Nervous System (ed 4). Lyon, France, IARC, 2007, pp 33-49
Kleihues P, Burger PC, Aldape KD, et al: Glioblastoma, in Louis DN, Ohgaki H, Wiester OD, et al (eds): WHO Classification of Tumours of the Central Nervous System (ed 4). Lyon, France, IARC, 2007, pp 33-49
2
84871465429
Central Brain Tumor Registry of the United States: Statistical Report: Primary Brain Tumors in the United States, 1998-2002. Hinsdale, IL, Central Brain Tumor Registry of the United States, 2005
Central Brain Tumor Registry of the United States: Statistical Report: Primary Brain Tumors in the United States, 1998-2002. Hinsdale, IL, Central Brain Tumor Registry of the United States, 2005
3
0036705582
The Brain Tumor Cooperative Group NIH Trial 87-01: A randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine
Selker RG, Shapiro WR, Burger P, et al: The Brain Tumor Cooperative Group NIH Trial 87-01: A randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51:343-355, 2002
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: A report from EORTC Brain Tumor Group study 26951
van den Bent MJ, Dubbink HJ, Sanson M, et al: MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: A report from EORTC Brain Tumor Group study 26951. J Clin Oncol 27:5881-5886, 2009
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide
Wick W, Hartmann C, Engel C, et al: NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874-5880, 2009
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
Cairncross G, Berkey B, Shaw E, et al: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2014, 2006
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial
van den Bent MJ, Carpentier AF, Brandes AA, et al: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715-2722, 2006
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha
Zhao S, Lin Y, Xu W, et al: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324:261-265, 2009
